TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02909946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal Infection Control Program
Description: 1. Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~2. Hand hygiene education to residents and families (resident-level intervention).~3. Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~4. Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~5. Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention).
Study: NCT02164474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at \~85-90% peak oxygen uptake \[VO2peak\] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at \~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Training
Description: Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at \~85-90% peak oxygen uptake \[VO2peak\] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at \~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
Study: NCT00739674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Salt Diet
Description: Low-salt intake diet (Dietary Approaches to Stop Hypertension \[DASH\]) including:~* Healthy diet~* Reduction in sodium intake to less than 2300 mmol/day~* Low alcohol consumption (less than 2 standard drinks/day)
Study: NCT00804791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Lubricant Eye Drops
Description: artificial tears solution for lubricating the cornea

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unisol 4 Saline Solution
Description: saline solution for irrigating the cornea
Study: NCT00787891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
Study: NCT00671697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study: NCT02032121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood specimen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Study: NCT00254904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Cisplatin
Description: Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
Study: NCT01068132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
Study: NCT04625309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive sports
Description: This will be the number of hours per week the subjects actively partake in adaptive sports teams.
Study: NCT03938168

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy, fecal sample
Description: Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy, fecal sample
Description: Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
Study: NCT03164902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Medicine
Description: The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
Study: NCT01871532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f®
Study: NCT01575769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RoActemra/Actemra (tocilizumab)
Description: Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
Study: NCT02056756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study: NCT04722380

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: periodontal regenerative surgery
Description: Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal regenerative surgery
Description: Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
Study: NCT03031990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person yoga for fertility group
Description: The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online yoga for fertility group
Description: The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In person discussion only group
Description: The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
Study: NCT03786224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
Study: NCT01253941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mud bath Therapy
Description: patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
Study: NCT03838601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET-4
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
Study: NCT02921906

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein meal
Description: Breakfast with high protein / low carbohydrate content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein meal
Description: Breakfast with high protein / low carbohydrate content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein meal
Description: Breakfast with high protein / low carbohydrate content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate meal
Description: Breakfast with high carbohydrate / low protein content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal
Description: Breakfast with high carbohydrate / low protein content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate meal
Description: Breakfast with high carbohydrate / low protein content

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting state - sulphonylurea only
Description: People with diabetes take sulphonylurea medication in the absence of any food stimulus
Study: NCT01245127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaris
Description: * Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks.
Study: NCT01478581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03842761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study: NCT01037140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: oral cholecalciferol tablets of 175 micrograms daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo tablets similar to active comparator
Study: NCT02557620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously (s.c., under the skin)once daily or once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously (s.c., under the skin)once daily or once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)once daily or once weekly.
Study: NCT03061149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound treatment
Study: NCT02557620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)once daily or once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)once daily or once weekly.
Study: NCT03839056

Intervention type: DEVICE
Intervention: IC+PIEB+PCEA high flow
Description: Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine

Intervention type: DEVICE
Intervention: PIEB+PCEA high flow
Description: Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine

Intervention type: DEVICE
Intervention: PIEB+PCEA standar flow
Description: Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine
Study: NCT03188302

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of stool samples
Description: The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
Study: NCT03987867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cell
Description: CIK cell injection
Study: NCT02968446

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 4 placebo
Description: subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 Vitamin D
Description: subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valchlor
Description: Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valchlor
Description: Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
Study: NCT01858441

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone Acetate
Study: NCT01500252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patellar Replacement Prosthesis
Description: The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profix TKR with Patellar Retention
Description: All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
Study: NCT03115827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Carbidopa 200mg twice a day
Study: NCT02676947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Study: NCT02798224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-assist: Colon Health
Description: Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthwise Educational Program
Description: Online access to fact sheets that provide basic information about colorectal cancer and screening.
Study: NCT02463396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT for ADHD
Study: NCT01301287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorella
Study: NCT02191878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKM-080301
Description: TKM-080301 intravenous infusion
Study: NCT00711230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: glucose/dextrose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: glucose/dextrose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: glucose/dextrose
Study: NCT03084094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Non invasive brain modulation at a 2mA current during 20minutes
Study: NCT01379040

Intervention type: OTHER
Intervention: Cystic Fibrosis patients
Study: NCT01080534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 5 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 5 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT03987867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: IBI308 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome paclitaxel
Description: Liposome paclitaxel injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin injection